Description
Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.Application：Pomalidomide has been used:to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides；for apoptosis studies and intracellular calcium analysis；as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells